The MVA vector expressing the F protein of bovine respiratory syncytial virus is immunogenic in systemic and mucosal immunization routes = El vector viral MVA que expresa la proteína F del virus respiratorio sincicial bovino es inmunogénico al administrarse por vía sistémica y por mucosas

Bovine respiratory syncytial virus (BRSV) affects both beef and dairy cattle, reaching morbidity and mortality rates of 60---80% and 20%, respectively. The aim of this study was to obtain a recombinant MVA expressing the BRSV F protein (MVA-F) as a vaccine against BRSV and to evaluate the immune res...

Descripción completa

Detalles Bibliográficos
Autores: Ferella, Alejandra, Mozgovoj, Marina Valeria, Garanzini, Debora Patricia, Dus Santos, Maria Jose, Calamante, Gabriela, Del Medico Zajac, Maria Paula
Tipo de recurso: artículo
Estado:Versión aceptada para publicación
Fecha de publicación:2023
País:Argentina
Institución:Instituto Nacional de Tecnología Agropecuaria
Repositorio:INTA Digital (INTA)
Idioma:inglés
OAI Identifier:oai:localhost:20.500.12123/16519
Acceso en línea:http://hdl.handle.net/20.500.12123/16519
https://www.sciencedirect.com/science/article/pii/S0325754123000834
https://doi.org/10.1016/j.ram.2023.07.006
Access Level:acceso abierto
Palabra clave:Bovine Respiratory Syncytial Virus
Vaccines
Immune Response
Virus Sincitial Respiratorio Bovino
Vacuna
Respuesta Inmunológica
Modified Vaccinia Ankara Virus
Virus Vaccinia Ankara Modificado
Descripción
Sumario:Bovine respiratory syncytial virus (BRSV) affects both beef and dairy cattle, reaching morbidity and mortality rates of 60---80% and 20%, respectively. The aim of this study was to obtain a recombinant MVA expressing the BRSV F protein (MVA-F) as a vaccine against BRSV and to evaluate the immune response induced by MVA-F after systemic immunization in homologous and heterologous vaccination (MVA-F alone or combined with a subunit vaccine), and after intranasal immunization of mice. MVA-F administered by intraperitoneal route in a homologous scheme elicited levels of neutralizing antibodies similar to those obtained with inactivated BRSV as well as better levels of IFN- secretion. In addition, nasal administration of MVA-F elicited local and systemic immunity with a Th1 profile. This study suggests that MVA-F is agood candidate for further evaluations combining intranasal and intramuscular routes, in order to induce local and systemic immune responses, to improve the vaccine efficacy against BRSV infection.

Similares en LA Referencia